By browsing our site you agree to our use of cookies. You will only see this message once. Find out more

Radiopharmaceutical Products and Generators [488639].

Contract notice

Supplies

Directive 2014/24/EU

Section I: Contracting authority

I.1)Name and addresses
Procurement and Logistics Service
Supplies Centre, Gransha Hospital
Londonderry
BT47 6YZ
United Kingdom
E-mail:
NUTS code: UK

Internet address(es):

Main address: https://etendersni.gov.uk/epps

Address of the buyer profile: https://etendersni.gov.uk/epps

I.1)Name and addresses
Belfast Health and Social Care Trust
A Floor, Belfast City Hospital, Lisburn Road
Belfast
BT9 7AB
United Kingdom
E-mail:
NUTS code: UK

Internet address(es):

Main address: https://etendersni.gov.uk/epps

Address of the buyer profile: https://etendersni.gov.uk/epps

I.1)Name and addresses
Western Health and Social Care Trust
Altnagelvin Area Hospital, Glenshane Road
Londonderry
BT47 6SB
United Kingdom
E-mail:
NUTS code: UK

Internet address(es):

Main address: https://etendersni.gov.uk/epps

Address of the buyer profile: https://etendersni.gov.uk/epps

I.2)Joint procurement
The contract involves joint procurement
I.3)Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at: https://etendersni.gov.uk/epps
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be submitted electronically via: https://etendersni.gov.uk/epps
I.4)Type of the contracting authority
Body governed by public law
I.5)Main activity
Health

Section II: Object

II.1)Scope of the procurement
II.1.1)Title:

Radiopharmaceutical Products and Generators [488639].

II.1.2)Main CPV code
33000000
II.1.3)Type of contract
Supplies
II.1.4)Short description:

Radiopharmaceutical Products and Generators [488639].

II.1.5)Estimated total value
II.1.6)Information about lots
This contract is divided into lots: yes
Tenders may be submitted for maximum number of lots: 32
II.2)Description
II.2.1)Title:

Ioflupane I-123

Lot No: 1
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 2 353 950.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

MIBG I-123 (metaiodobenzylguanidine)

Lot No: 2
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 158 090.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Sodium Iodide I-123

Lot No: 3
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 112 250.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Sodium Iodide Therapy Capsule I-131

Lot No: 4
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 179 470.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Sodium Iodide Liquid I-131

Lot No: 5
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 1 510.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Therapeutic MIBG I-131 (metaiodobenzylguanidine)

Lot No: 6
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 247 480.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Chromium EDTA Cr-51 (Ethylene Diamine Tetra-acetic Acid)

Lot No: 7
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 73 610.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Sodium Chromate Cr-51

Lot No: 8
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 26 820.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Gallium Citrate Ga-67

Lot No: 9
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 2 560.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Generator Krypton Gas Kr-81

Lot No: 10
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 260 000.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Generator Technetium Mo-99/Tc-99m

Lot No: 11
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 841 190.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Samarium Sm-135

Lot No: 12
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 51 960.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Selenium Homocholic Acid Taurine/Tauroselcholic Acid Se-75

Lot No: 13
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 158 790.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Radium Dichloride Ra-223

Lot No: 14
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 3 168 000.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Indium DTPA In-111 (Diethylenetriamine Pentaacetate)

Lot No: 15
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 3 330.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Thallium Tl-201

Lot No: 16
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 2 320.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

DMSA (Dimercaptosuccinic Acid)

Lot No: 17
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 26 560.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

DTPA (Diethylenetriamine Pentaacetate)

Lot No: 18
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 8 980.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Exametazime

Lot No: 19
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 115 000.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

HDP (Hydroxymethylene Diphosphonate)

Lot No: 20
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 46 150.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Human Albumin Nanocolloid

Lot No: 21
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 125 650.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

MAA (Macro Aggregated Albumin)

Lot No: 22
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 43 280.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Mertiatide

Lot No: 23
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 95 700.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Mebrofenin

Lot No: 24
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 33 560.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

MIBI (Sestamibi - Methoxyisobutylisonitrile)

Lot No: 25
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 205 620.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Sodium Pyrophosphate

Lot No: 26
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 1 840.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Sulesomab

Lot No: 27
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 14 060.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Tetrofosmin

Lot No: 28
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 141 200.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Tin Colloid

Lot No: 29
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 4 800.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Indium Chloride In-111

Lot No: 30
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 4 380.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Sodium Phosphate P-32

Lot No: 31
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 58 040.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

II.2)Description
II.2.1)Title:

Yttrium Silicate Y-90

Lot No: 32
II.2.2)Additional CPV code(s)
33000000
II.2.3)Place of performance
NUTS code: UKN
II.2.4)Description of the procurement:

Radiopharmaceutical Products and Generators [488639].

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
Value excluding VAT: 15 960.00 GBP
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: yes
Description of options:

It is anticipated that this Framework Agreement will commence on 1st June 2017 for a duration of 2 years. The Client may at any time before the completion of the contract period invite the Contractor to agree to extend for any period up to and including 24 months commencing from the termination date of the original contract period.

II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

In section 1.2, it is stated that this procurement is a joint procedure and contract award is by a Central Purchasing Body. This contract is not a joint contract, it is a Central Purchasing Body Contract operated by BSO PaLS on behalf of the participants listed in section 1.1.

Section III: Legal, economic, financial and technical information

III.1)Conditions for participation
III.1.1)Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers
III.1.2)Economic and financial standing
III.1.3)Technical and professional ability
III.1.5)Information about reserved contracts
III.2)Conditions related to the contract
III.2.2)Contract performance conditions:
III.2.3)Information about staff responsible for the performance of the contract

Section IV: Procedure

IV.1)Description
IV.1.1)Type of procedure
Open procedure
IV.1.3)Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
Framework agreement with several operators
Envisaged maximum number of participants to the framework agreement: 3
In the case of framework agreements, provide justification for any duration exceeding 4 years: Not applicable.
IV.1.4)Information about reduction of the number of solutions or tenders during negotiation or dialogue
IV.1.6)Information about electronic auction
IV.1.8)Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: yes
IV.2)Administrative information
IV.2.1)Previous publication concerning this procedure
IV.2.2)Time limit for receipt of tenders or requests to participate
Date: 15/03/2017
Local time: 15:00
IV.2.3)Estimated date of dispatch of invitations to tender or to participate to selected candidates
IV.2.4)Languages in which tenders or requests to participate may be submitted:
English
IV.2.6)Minimum time frame during which the tenderer must maintain the tender
Tender must be valid until: 13/06/2017
IV.2.7)Conditions for opening of tenders
Date: 15/03/2017
Local time: 15:30

Section VI: Complementary information

VI.1)Information about recurrence
This is a recurrent procurement: no
VI.2)Information about electronic workflows
VI.3)Additional information:
VI.4)Procedures for review
VI.4.1)Review body
Business Services Organisation, PaLS
77 Boucher Crescent
Belfast
BT12 6HU
United Kingdom
VI.4.2)Body responsible for mediation procedures
VI.4.3)Review procedure
VI.4.4)Service from which information about the review procedure may be obtained
VI.5)Date of dispatch of this notice:
13/02/2017